Adamis Pharmaceuticals Corp

  • Health Technology
  • Pharmaceuticals: Other
  • Pharmaceuticals: Major
  • Manufacturing
  • Pharmaceutical Preparation Manufacturing


$0.5351 ▲6.977%

Last Close




0.4801 - 0.5196


0.3118 - 1.48

Join Discuss about ADMP with like-minded investors

@nepestheone #StockTraders.NET

MIC watchlist DATS - I think the edge is gone here. Probably will trade random and choppy going forward. NO EDGE = NO TRADE IO - Looks like potential HOT CHICK. No bias yet. Will let it extend. Ideally 2.50 rejection for a short ANY - Looking for an 8.00 / 8.20 rejection to short LMFA - Low hanging fruit. Ideally 4.50 / 4.80 / 5.00 / rejections to shot ADMP - Not much range on this. Maybe a 1.50 / 1.60 rejection with a 1.75 STOP MARA - Potential SELL THE NEWS [tomorrow] when Bitcoin ETF is live. Not touching today but putting it here so i dont forget

83 Replies 6 👍 10 🔥

@maletone #StockTraders.NET

hopefully $ADMP & $IO go higher

121 Replies 9 👍 13 🔥

@maletone #StockTraders.NET

adding $ADMP to the list

50 Replies 11 👍 6 🔥

@viking #StockTraders.NET

Upside: -NOVN +32% (reports positive topline results from pivotal Phase III trial of SB206 in patients with molluscum contagiosum) -PGEN +28% (announces positive topline results from Phase 1b/2a study of AG019 ActoBiotics, a Novel Therapy designed to address the underlying cause of Type 1 Diabetes; primary endpoints were met) -GENE +15% (US Patent Office grants foundational pharmacogenomic patent) -MX +15% (confirms 21% improved rival bid of $35/shr cash unsolicited proposal from Cornucopia Investment Partners) -ZDGE +9.5% (earnings, guidance) -ATC +8.4% (MKS Instruments said to have approached Atotech for acquisition) -ADMP +5.9% (provides update on clinical trial start-up progress for tempol in the treatment of COVID-19) -RFP +5.6% (announces $1/share Special Dividend, and $50M in lumber investments) -PLAY +5.3% (earnings, guidance) -AUTL +5.1% (presents new data on obe-cel in r/r Indolent B cell lymphomas and gives an update of obe-cel in r/r Adult ALL at the European Hematology Association Virtual Congress) -MBIO +5.0% (announced updated interim Phase 1/2 data for MB-106) -TYME +5.0% (comprehensive strategic review identified breast cancer as a priority indication for development, a focus on second-line pancreatic cancer, and continuation of trial in high-risk sarcomas) -LIFE +2.5% (presents poster demonstrating functional selectivity of second Anti-NRP2 Antibody) -OCGN +1.4% (Roth Capital broker downgrade) -AVO +1.3% (earnings, guidance) Downside: -ORPH -52% (application for MIPLYFFA under priority review with FDA, expected Prescription Drug User Fee Act action date of June 17; company not aware for reason for stock volatility) -VRTX -14% (reports primary endpoint achieved in Phase 2 Study of VX-864 in Alpha-1 Antitrypsin Deficiency but magnitude of treatment effect observed unlikely to translate into substantial clinical benefit) -CVAC -11% (downside momentum) -INCY -4.0% (FDA extendes the New Drug Application review period for ruxolitinib cream for the treatment of atopic dermatitis) -ADC -3.9% (prices 4.0M shares at implied $71.50/shr to raise $286M) -SNOW -3.7% (provides 2029 financial targets) -ELY -3.6% (to join S&P MidCap 400) -LTHM -3.2% (prices 13M shares at $17.50/shr) -AGNC -3.1% (reports tangible net book value) -RCL -2.1% (two guests aboard Celebrity Millennium test positive for COVID during required end-of-cruise testing) -CHWY -1.4% (earnings, guidance)

54 Replies 13 👍 14 🔥

@maletone #StockTraders.NET

should have held some more $ADMP and reshort the bunce

99 Replies 12 👍 10 🔥

@soheil.n #StockTraders.NET

$ADMP ripping...SSR is on

57 Replies 10 👍 9 🔥

@soheil.n #StockTraders.NET

watchlist: $BB, $CLII, $SCYX, $ADMP, $NNDM, $QTT -if i can get borrows later in the day

68 Replies 7 👍 8 🔥

@Navneet #droscrew

have a look on $admp

106 Replies 14 👍 9 🔥

Key Metrics

Market Cap

74.90 M



Avg. Volume

508 K

Shares Outstanding

149.73 M



Public Float


Next Earnings Date


Next Dividend Date

Company Information

Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. The company's SYMJEPI (epinephrine) Injection products are approved by the FDA for use in the emergency treatment of acute allergic reactions, including anaphylaxis. Adamis' naloxone injection product candidate, ZIMHI, for the treatment of opioid overdose is currently under FDA review. Adamis is developing additional products, including treatments for acute respiratory diseases, such as COVID-19, influenza, asthma, and COPD. The company's subsidiary, US Compounding Inc., compounds sterile prescription drugs, and certain nonsterile drugs for human and veterinary use by hospitals, clinics, surgery centers, and vet clinics throughout most of the United States. Forward Looking Statements

CEO: Dennis Carlo


HQ: 11682 El Camino Real Ste 300 San Diego, 92130 California

Related News